Publication Date: 2022/01/18

NEW YORK/COPENHAGEN, 18 January 2022 – UNICEF has signed several long term agreements (LTA) with suppliers for the procurement of the new antiviral medicine Molnupiravir.  

UNICEF procurement of Molnupiravir is dependent on clinical recommendations, regulatory approvals and compliance with UNICEF quality assurance requirements. In December, the US Food and drug administration issued an emergency use authorization for the use of Molnupiravir in the treatment of COVID19 in certain patients. Molnupiravir is currently under assessment by WHO.

These agreements will help ensure that low and middle-income countries (LMICs) have timely access to novel COVID-19 therapies.  UNICEF will continue to work with ACT-A (Access to COVID-19 Tools Accelerator) partners and industry to ensure supply availability, achieve affordable prices and capacity to meet country needs. Supply will also be available for ACT-A partners wishing to deploy Molnupiravir in countries.  

UNICEF will work closely with other ACT-A partners such as WHO, the Global Fund and Unitaid to ensure an equitable access to supply for LMICs.  


Remove this and add your HTML markup here.


UNICEF is the world’s leading humanitarian organization focused on children. We work in the most challenging areas to provide protection, healthcare and immunizations, education, safe water and sanitation and nutrition. As part of the United Nations, our unrivaled reach spans more than 190 countries and territories, ensuring we are on the ground to help the most disadvantaged children. While part of the UN system, UNICEF relies entirely on voluntary donations to finance our life-saving work. Please visit and follow us on Twitter, Facebook and Instagram.

For further information please contact: